We are a preclinical-stage therapeutics company leveraging human-identical molecules as new medicines to treat large patient populations underserved by current treatment options. Our initial drug candidates are based on bioactive oligosaccharides naturally produced in human milk, or HMOs, which directly modulate the immune system and other human cells as well as the gut microbiome.
We believe our synthetic biology-manufactured human-identical milk oligosaccharide, or HiMO, drug candidates have the potential to affect multiple pathways implicated in gut-brain axis disorders and certain inflammatory disorders, while reproducing the favorable safety and tolerability profile observed of HMOs. We are prioritizing the development of our drug candidates for disorders where available treatment options are inadequately serving patients due to safety or tolerability issues and where we have the potential to redefine the standard of care.
Our Team

Alex Martinez
CEO, Chairman & Co - Founder

Jason Ferrone
COO, President & Co - Founder

Emil Chuang
MB BS, (Syd), FRACP, Chief Medical Officer

Dustin Crawford
General Counsel and VP, Corporate Development

David Donahue
VP, Clinical Operations

Michelle David
MBA, Director, Operations and Corporate Development

Alyssa Palmquist
MBS, Associate Director, Corporate Affairs and Patient Engagement

Nichole Ghazanfarpour
Executive Assistant
Board of Directors

Alex Martinez

Jason Ferrone
Scientific Advisory Board

Angela Christiano, PhD

David Newburg, PhD

John McCoy, PhD

Ardythe Morrow, PhD
Medical Advisory Board

Brian Lacy, MD, PhD

Anthony Lembo, MD

Nicholas Talley, MD, PhD

Purna Kashyap, MB BS, PhD

Baharak Moshiree

Daniel Lovell, MD
